- Trial Phase
- Approved
- Time to Market
- Already on the market (approved 2007); US generic competition began May 2025
- Why 2/10
- No hard, dated catalyst for Tasigna in the next ~12 months — it is an already-approved drug whose US exclusivity ended in 2025; no pending PDUFA, pivotal readout, or advisory committee is scheduled, and it is a small legacy asset inside a mega-cap portfolio, so a score of 2 (small part of a large pipeline, nothing scheduled) applies.
For a Tasigna-specific trade, there is nothing binary to trade on: the patent cliff already happened (first US generic launched May 27, 2025). Watch Novartis quarterly reports for how fast nilotinib revenue erodes and whether generic share stabilizes — that is a slow bleed, not a catalyst. NVS itself is a diversified mega-cap (analyst consensus 'hold', mean price target ~$157.15 vs. ~$156.24 price), so Tasigna moves almost nothing in the stock; any Tasigna news is noise for NVS shareholders.
Price Chart
Executive Summary
Tasigna (nilotinib) is Novartis' second-generation BCR-ABL tyrosine kinase inhibitor for Philadelphia-chromosome-positive chronic myeloid leukemia, approved by the FDA on October 29, 2007 and now indicated for adults and children ≥1 year with newly diagnosed chronic-phase Ph+ CML as well as resistant/intolerant disease. It is a mature, fully commercialized drug that lost US exclusivity in 2025 — Apotex launched the first generic nilotinib in the US on May 27, 2025 — and 2024 US sales were already ~$848M and eroding, with Novartis' own Q4 2025 release citing 'significant US generic entries' as a drag. There is no pending regulatory decision or pivotal readout for Tasigna, so it is a declining revenue line inside a diversified mega-cap rather than a binary story.
How It Works
Tasigna is a once- or twice-daily oral pill for chronic myeloid leukemia (CML). It blocks an abnormal enzyme called BCR-ABL that is created when patients carry the 'Philadelphia chromosome'; that enzyme drives leukemia cells to multiply out of control. By switching BCR-ABL off, Tasigna stops the cancer cells from growing — it is a second-generation 'tyrosine kinase inhibitor' that can work in patients who fail or cannot tolerate the older drug imatinib (Gleevec), and it is also approved as first-line treatment.
Trial Status
Marketed drug with no active Novartis registration trials in SecBot's trial database; the only locally tracked nilotinib trial is a COMPLETED, Georgetown University-sponsored Phase 2 off-label repurposing study in Parkinson's disease (NCT02954978). FDA data for 2026 shows a Class III voluntary recall of Cipla's generic nilotinib capsules and an AvKARE generic safety-labeling update (QT-prolongation warning), reflecting the mature generic phase of the product lifecycle.
The Two-Sided Case
Upcoming Catalysts
- None scheduled for Tasigna — no PDUFA, pivotal readout, or FDA advisory meeting in the next ~12 months.
- Quarterly Novartis sales reports: watch the pace of nilotinib erosion vs. generic share.
- Occasional headlines possible from the completed Georgetown Phase 2 study of nilotinib in Parkinson's disease (off-label repurposing, not Novartis-sponsored).
- Any label/litigation news around nilotinib generics (recalls, safety labeling) is low-impact noise for NVS.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVARTIS AG 6-K NVS ·Originating report